|
|
|
20.04.26 - 23:54
|
Compass Pathways CEO on Trump′s Order to Expand Psychedelics Research (Bloomberg)
|
|
|
Shares of companies involved in psychedelic-tied therapies surged Monday after President Donald Trump signed an executive order to expedite research and access. US-traded shares of Compass Pathways spiked as much as 53% while AtaiBeckley surged by 37%. GH Research jumped 34% and Definium Therapeutics rallied 16%. The AdvisorShares Psychedelics ETF (PSIL) also climbed as much as 20% — touching its highest intraday level since July 2023. The new order directs the US Food and Drug Administration to issue expedited review vouchers to psychedelics with a so-called breakthrough designation, shortening the review time to one to two months from six to ten months. AtaiBeckley, Definium and Compass Pathways all have therapies with breakthrough status. Compass Pathways CEO Kabir Nath joins Bloomberg Businessweek Daily to discuss. He speaks with Carol Massar and Tim Stenovec. (Source: Bloomberg)...
|
|
|
|
|
|
|
|
|
|
|
08.04.26 - 12:03
|
AtaiBeckley′s BPL-003 Shows Rapid, Durable Antidepressant Response in Treatment-Resistant Depression Patients on SSRIs; Phase 2a Data Published in CNS Drugs (GlobeNewswire EN)
|
|
|
NEW YORK, April 08, 2026 (GLOBE NEWSWIRE) -- AtaiBeckley Inc. (NASDAQ: ATAI) (“AtaiBeckley” or “Company”), a clinical-stage biotechnology company on a mission to transform patient outcomes by developing rapid-acting, durable and convenient mental health treatments, today announced peer-reviewed Phase 2a results (NCT05660642) in CNS Drugs demonstrating that a single intranasal dose of BPL-003 (mebufotenin benzoate), which holds FDA Breakthrough Therapy Designation, achieved rapid and sustained reductions in MADRS scores from baseline in participants with treatment-resistant depression (TRD) who remained on stable SSRI therapy throughout the study (n=12). A 66.7% antidepressant response rate (≥50% reduction from baseline MADRS score) was observed at Day 2 in both the 10 mg (n=6) and 12 mg (n=6) cohorts, with 83% (5/6) of participants in the 10 mg cohort and 66.7% (4/6) of participants in the 12 mg cohort maintaining a response at Week 12. BPL-003 was generally well tolerated with no serious adve...
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
10.03.26 - 15:00
|
AtaiBeckley: Lead Candidate Could Be Game-Changer For TRD Patients, Say Analysts (Benzinga)
|
|
|
AtaiBeckley's lead candidate, BPL-003, showed promising results in TRD. Analysts expect it to be a game changer and command premium pricing.
Latest Ratings for ATAI
DateFirmActionFromTo Nov 2021Maxim GroupInitiates Coverage OnBuy Nov 2021HC Wainwright & Co.MaintainsBuy Nov 2021Credit SuisseMaintainsOutperform
View More Analyst Ratings for ATAI
View the Latest Analyst Ratings
Importance Rank:
1
read more...
|
|
|
|
|
|
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
